Genmab A/S Dkk (GNMSF) 96.4500 $GNMSF
Genmab Announces European Regulatory Submission for Daratumumab in Double Refractory Multiple Myeloma
GlobeNewswire - Wed Sep 09, 6:38AM CDT
-- MAA submitted to EMA by Janssen for daratumumab in multiple myeloma
GEN: 7.03 (-0.10)
Global Malignant Glioma Pipeline Review 2015
M2 - Tue Sep 08, 5:31AM CDT
Research and Markets (http://www.researchandmarkets.com/research/5ms2wz/malignant_glioma) has announced the addition of the "Malignant Glioma - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Malignant Glioma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Malignant Glioma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Advantagene, Inc. - Amgen Inc. - AstraZeneca Plc - BBB Therapeutics B.V. - Eisai Co., Ltd. - Eli Lilly and Company - Genmab A/S - Lipopharma Therapeutics SL - MediGene AG - Nuo Therapeutics, Inc. - Pfizer Inc. - Stemline Therapeutics, Inc. - Tiziana Life Sciences Plc - Vicus Therapeutics, LLC - ZIOPHARM Oncology, Inc. For more information visit http://www.researchandmarkets.com/research/5m...ant_glioma
ZIOP: 10.62 (+0.80), PFE: 32.97 (+0.35), AZN: 33.30 (+0.02), AMGN: 153.21 (+0.07), LLY: 81.80 (+0.96), STML: 10.84 (+0.59)
U.S. FDA Grants Priority Review for Daratumumab for Double Refractory Multiple Myeloma
GlobeNewswire - Fri Sep 04, 1:25PM CDT
-- U.S. FDA grants Priority Review to daratumumab
GEN: 7.03 (-0.10)
Major Shareholder Announcement
GlobeNewswire - Wed Sep 02, 3:14PM CDT
Company Announcement
GEN: 7.03 (-0.10)
Genmab Enters Commercial License Agreement with Novo Nordisk for DuoBody Technology
GlobeNewswire - Fri Aug 14, 5:37AM CDT
-- Two commercial DuoBody
NVO: 56.95 (+0.37), GEN: 7.03 (-0.10)
Genmab Announces Financial Results for the First Half of 2015
GlobeNewswire - Wed Aug 12, 12:59AM CDT
Interim Report First Half 2015
Bladder Cancer Pipeline Review, H1 2015 - 80 Companies & 119 Drug Profiles
M2 - Fri Jul 31, 8:42AM CDT
Research and Markets (http://www.researchandmarkets.com/research/shdv3w/bladder_cancer) has announced the addition of the "Bladder Cancer - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Bladder Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Bladder Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development (Partial List) - Advaxis, Inc. - Alligator Bioscience AB - Alnylam Pharmaceuticals, Inc. - Altor BioScience Corporation - Amgen Inc. - AndroScience Corporation - APIM Therapeutics AS - Arno Therapeutics, Inc. - Ascenta Therapeutics, Inc. - Astellas Pharma Inc. - AstraZeneca Plc - AuraSense Therapeutics, LLC - AVEO Pharmaceuticals, Inc. - AvidBiotics Corp. - Bavarian Nordic A/S - Bayer AG - BioCancell Ltd - Bioncotech Therapeutics S.L. - Biotest AG - cCAM Biotherapeutics Ltd. - Celgene Corporation - Cold Genesys, Inc. - Daiichi Sankyo Company, Limited - Dompe Farmaceutici S.p.A. - DormaTarg, Inc. - Eisai Co., Ltd. - Eli Lilly and Company - EntreChem, S.L. - Esperance Pharmaceuticals, Inc. - Evotec AG - F. Hoffmann-La Roche Ltd. - Gene Signal International SA - Genmab A/S - GlaxoSmithKline Plc - Heat Biologics, Inc. For more information visit http://www.researchandmarkets.com/research/sh...der_cancer
HTBX: 4.52 (+0.11), ADXS: 16.51 (+0.55), AMGN: 153.21 (+0.07), LLY: 81.80 (+0.96), GSK: 40.26 (+0.02), AZN: 33.30 (+0.02), AVEO: 1.36 (unch), CELGZ: 1.93 (+0.07)
Pemphigus Vulgaris Pipeline Review, H1 2015 - 5 Companies & 7 Drug Profiles
M2 - Tue Jul 28, 8:14AM CDT
Research and Markets (http://www.researchandmarkets.com/research/ms9fp4/pemphigus) has announced the addition of the "Pemphigus Vulgaris - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Pemphigus Vulgaris, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Pemphigus Vulgaris and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Biogen, Inc. - Genmab A/S - HanAll Biopharma Co., Ltd. - Immunomedics, Inc. - Novartis AG Drug Profiles - DP-C006 - HL-161 - ofatumumab - rituximab - T-Cell Therapy for Pemphigus Vulgaris - VAY-736 - veltuzumab For more information visit http://www.researchandmarkets.com/research/ms9fp4/pemphigus
IMMU: 2.22 (+0.01), NVS: 96.55 (+0.28)
Genmab Announces Submission of Supplemental Biologics License Application to FDA for Ofatumumab as Maintenance Therapy for Relapsed CLL
GlobeNewswire - Wed Jul 22, 7:27AM CDT
Company Announcement
GEN: 7.03 (-0.10)
Endometrial Cancer Therapeutics Pipeline Review, H1 2015 - 35 Companies & 48 Drug Profiles
M2 - Tue Jul 21, 3:45AM CDT
Research and Markets (http://www.researchandmarkets.com/research/psfwd9/endometrial) has announced the addition of the "Endometrial Cancer - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Endometrial Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Endometrial Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Acceleron Pharma, Inc. - Aeterna Zentaris Inc. - Ariad Pharmaceuticals, Inc. - Arno Therapeutics, Inc. - ArQule, Inc. - AstraZeneca Plc - AVEO Pharmaceuticals, Inc. - BioMarin Pharmaceutical Inc. - Boehringer Ingelheim GmbH - Critical Outcome Technologies Inc. - Daiichi Sankyo Company, Limited - Eisai Co., Ltd. - Esperance Pharmaceuticals, Inc. - Exelixis, Inc. - Farmsintez - Galena Biopharma, Inc. - Genentech, Inc. - Genmab A/S - GlaxoSmithKline Plc - Gradalis Inc. - ImmunoGen, Inc. - Incyte Corporation - Karyopharm Therapeutics, Inc. - Merck & Co., Inc. - Merck KGaA - Millennium Pharmaceuticals, Inc. - Novartis AG - OncoHoldings, Inc. - Oncothyreon Inc. - Otsuka Holdings Co., Ltd. - Pharma Mar, S.A. - Puma Biotechnology, Inc. - Sanofi - Scancell Holdings Plc - Shenogen Pharma Group Ltd. Drug Profiles - (ponatinib hydrochloride ridaforolimus) - ???Pb-TCMC-Trastuzumab - AEZS-125 - afuresertib hydrochloride trametinib dimethyl sulfoxide - ARQ-092 - AV-203 - AZD-2014 - AZD-5363 - buparlisib hydrochloride - cabozantinib s-malate - cancer vaccine - Cell Therapy for Oncology - CLR-457 - COTI-2 - cridanimod - dalantercept - EP-200 - epacadostat - everolimus - FROST-450 - GALE-301 - GDC-0927 - GSK-2636771 - HO-3867 - HuMax-TF-ADC - INCB-54828 - lenvatinib - lurbinectedin - mirvetuximab soravtansine - MK-2206 - Modi-1 - Monoclonal Antibody to Inhibit L1CAM for Ovarian and Endometrial Cancer - neratinib - nintedanib - onapristone ER For more information visit http://www.researchandmarkets.com/research/ps...ndometrial
BMRN: 132.88 (-0.20), ARQL: 1.71 (-0.01), GALE: 1.70 (-0.01), EXEL: 5.91 (+0.04), XLRN: 33.62 (+1.44), INCY: 131.01 (+6.51), IMGN: 13.86 (+0.59), GSK: 40.26 (+0.02), ONTY: 3.30 (-0.09), AZN: 33.30 (+0.02), MRK: 52.09 (-0.63), AVEO: 1.36 (unch), PBYI: 103.28 (+6.59), KPTI: 14.95 (+0.41), NVS: 96.55 (+0.28)
Major Shareholder Announcement for Genmab A/S
GlobeNewswire - Fri Jul 10, 10:54AM CDT
Genmab A/S (OMX:GEN) announces under reference to Section 29 of the Danish Securities Trading Act that ATP has informed us that ATP and AES as of July 10, 2015 have reduced their ownership of the share capital and voting rights in Genmab A/S to below the 5% threshold.
GEN: 7.03 (-0.10)
Genmab Announces Completion of Rolling Submission of Biologics License Application for Daratumumab in Multiple Myeloma and Achievement of a USD 15 Million Milestone
GlobeNewswire - Thu Jul 09, 12:53PM CDT
-- Submission of rolling BLA to US FDA for daratumumab in multiple myeloma completed by Janssen Biotech, Inc.
GEN: 7.03 (-0.10)
Relapsing Remitting Multiple Sclerosis (RRMS) Therapeutics Pipeline Review, H1 2015 - 27 Companies & 33 Drug profiles
M2 - Thu Jul 09, 9:49AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hdmmpc/relapsing) has announced the addition of the "Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Relapsing Remitting Multiple Sclerosis (RRMS), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Relapsing Remitting Multiple Sclerosis (RRMS) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AbbVie Inc. - Actelion Ltd - Allozyne, Inc. - Amarna Therapeutics B.V. - Antisense Therapeutics Limited - Biogen, Inc. - Cognosci, Inc. - F. Hoffmann-La Roche Ltd. - Forward Pharma A/S - Genmab A/S - GlaxoSmithKline plc - Iltoo Pharma - Mapi Pharma Ltd. - MedImmune, LLC - Merck KGaA - Mitsubishi Tanabe Pharma Corporation - Neurotec Pharma SL - Novartis AG - Nuron Biotech, Inc. - Octapharma AG - Opexa Therapeutics, Inc. - RedHill Biopharma Ltd. - Sanofi - Synthetic Biologics, Inc. - Teva Pharmaceutical Industries Limited - XenoPort, Inc. - Zydus Cadila Healthcare Limited Drug Profiles - (rifabutin clarithromycin clofazimine) - aldesleukin - ATL-1102 - ATXMS-1467 - AZ-17 - Cell Therapy for Relapsing Remitting Multiple Sclerosis - COG-133 - daclizumab - diazoxide - dimethyl fumarate - estriol - Gene Therapy for Relapsing and Remitting Multiple Sclerosis - glatiramer acetate ER - GSK-239512 - Guanabenz - HR-411 - hydralazine - imilecleucel-t - immune globulin (human) - interferon beta-1b - laquinimod sodium - MEDI-551 - MT-1303 - ofatumumab - olesoxime - opicinumab - Pegylated Interferon-Beta-1b - ponesimod - siponimod - Small Molecule to Target CTLA4 and IFNGR for RRMS - vatelizumab - VAY-736 - XP-23829 For more information visit http://www.researchandmarkets.com/research/hdmmpc/relapsing
MAPI: (), RDHL: 14.47 (+0.62), GSK: 40.26 (+0.02), XNPT: 7.14 (+0.25), SYN: 2.62 (+0.18), OPXA: 0.44 (unch), FWP: 25.68 (+0.46), TEVA: 63.66 (+1.62), ABBV: 59.35 (-0.23), NVS: 96.55 (+0.28)
Lung Adenocarcinoma Pipeline Review, H1 2015 - 19 Companies & 27 Drug Profiles
M2 - Thu Jul 09, 6:34AM CDT
Research and Markets (http://www.researchandmarkets.com/research/3vrdth/lung) has announced the addition of the "Lung Adenocarcinoma - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Lung Adenocarcinoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Lung Adenocarcinoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Amgen Inc. - Astex Pharmaceuticals, Inc. - AstraZeneca PLC - AVEO Pharmaceuticals, Inc. - Axelar AB - Bayer AG - BioNumerik Pharmaceuticals, Inc. - Boehringer Ingelheim GmbH - DiNonA Inc. - Eisai Co., Ltd. - Genentech, Inc. - Genmab A/S - Immunomedics, Inc. - Incyte Corporation - Medisyn Technologies, Inc. - Pfizer Inc. - Sanofi - VG Life Sciences, Inc. - Vichem Chemie Research Ltd. Drug Profiles - 4-B4 - afatinib - AV-203 - AXL-1717 - AZD-6738 - BAY-1163877 - Cell Therapy to Activate CD40L and GM-CSF for Metastatic Lung Adenocarcinoma - dacomitinib - DBPR-112 - dimesna - hydroxychloroquine sorafenib tosylate - Interferon Lambda-1 Linked Fab Dimer - lenvatinib - MAG-Tn3 - MT-477 - ruxolitinib phosphate - SAR-408701 - Small Molecule for Cancer - Small Molecule to Inhibit EGFR for Oncology - Small Molecules to Activate PKM2 for Lung Adenocarcinoma - Small Molecules to Inhibit Lactate Dehydrogenase for Lung Adenocarcinoma - SNX-5422 - solitomab - Stem Cell Therapy for Oncology - TdCyd - TF-011 Monomethyl Auristatin E - Vaccine for Lung Adenocarcinoma For more information visit http://www.researchandmarkets.com/research/3vrdth/lung
IMMU: 2.22 (+0.01), PFE: 32.97 (+0.35), INCY: 131.01 (+6.51), AZN: 33.30 (+0.02), AVEO: 1.36 (unch), AMGN: 153.21 (+0.07)
Genmab Announces European Regulatory Submission for Ofatumumab as Maintenance Therapy for Relapsed CLL
GlobeNewswire - Tue Jul 07, 6:40AM CDT
Company Announcement
GEN: 7.03 (-0.10)
B-Cell Non-Hodgkin Lymphoma - Pipeline Review, H1 2015 - Profiles of 90 Companies
M2 - Thu Jun 11, 6:13AM CDT
Research and Markets (http://www.researchandmarkets.com/research/4w5fzl/bcell) has announced the addition of the "B-Cell Non-Hodgkin Lymphoma - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for B-Cell Non-Hodgkin Lymphoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for B-Cell Non-Hodgkin Lymphoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - B-Cell Non-Hodgkin Lymphoma Overview - Therapeutics Development - B-Cell Non-Hodgkin Lymphoma - Therapeutics under Development by Companies - B-Cell Non-Hodgkin Lymphoma - Therapeutics under Investigation by Universities/Institutes - B-Cell Non-Hodgkin Lymphoma - Pipeline Products Glance - B-Cell Non-Hodgkin Lymphoma - Products under Development by Companies - B-Cell Non-Hodgkin Lymphoma - Products under Investigation by Universities/Institutes - B-Cell Non-Hodgkin Lymphoma - Companies Involved in Therapeutics Development - B-Cell Non-Hodgkin Lymphoma - Therapeutics Assessment - Drug Profiles - B-Cell Non-Hodgkin Lymphoma - Recent Pipeline Updates - B-Cell Non-Hodgkin Lymphoma - Dormant Projects - B-Cell Non-Hodgkin Lymphoma - Discontinued Products - B-Cell Non-Hodgkin Lymphoma - Product Development Milestones - Appendix Companies Mentioned - Affimed Therapeutics AG - Bristol-Myers Squibb Company - Emergent BioSolutions Inc. - EpiZyme, Inc. - Erytech Pharma SA - F. Hoffmann-La Roche Ltd. - Genentech, Inc. - Genmab A/S - Gilead Sciences, Inc. - GlaxoSmithKline plc - Idera Pharmaceuticals, Inc. - Immune System Therapeutics Ltd. - ImmunoGen, Inc. - Merck & Co., Inc. - Millennium Pharmaceuticals, Inc. - Mirati Therapeutics Inc. - Molecular Templates Inc. - MorphoSys AG - Nordic Nanovector AS - Portola Pharmaceuticals, Inc. - Priaxon AG - ProNAi Therapeutics, Inc. - Redx Pharma Ltd - Regeneron Pharmaceuticals, Inc. - Respiratorius AB - Rhizen Pharmaceuticals SA - Sandoz Inc. - Sanofi - Takeda Pharmaceutical Company Limited - Teva Pharmaceutical Industries Limited - TG Therapeutics, Inc. For more information visit http://www.researchandmarkets.com/research/4w5fzl/bcell
PTLA: 49.77 (+3.03), EBS: 32.58 (+0.39), IMGN: 13.86 (+0.59), TGTX: 11.83 (+0.37), EPZM: 20.70 (+0.23), BMY: 59.22 (+0.47), GSK: 40.26 (+0.02), IDRA: 3.34 (+0.26), GILD: 109.63 (+2.38), MRK: 52.09 (-0.63), TEVA: 63.66 (+1.62), MRTX: 43.38 (+8.58), REGN: 533.30 (+2.08)
Waldenstrom Macroglobulinemia - Pipeline Review, H1 2015 - 18 Companies & 27 Drug Profiles
M2 - Wed Jun 10, 4:20AM CDT
Research and Markets (http://www.researchandmarkets.com/research/8pl7hb/waldenstrom) has announced the addition of the "Waldenstrom Macroglobulinemia - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Waldenstrom Macroglobulinemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Waldenstrom Macroglobulinemia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AbbVie Inc. - arGEN-X BV - Bayer AG - Calithera Biosciences, Inc. - Celgene Corporation - Genmab A/S - Gilead Sciences, Inc. - Idera Pharmaceuticals, Inc. - Immune System Therapeutics Ltd. - Incyte Corporation - Karyopharm Therapeutics, Inc. - Merck KGaA - Millennium Pharmaceuticals, Inc. - Nimbus Therapeutics, LLC - Nordic Nanovector AS - Novartis AG - Onyx Pharmaceuticals, Inc. - Pharmacyclics, Inc. Drug Profiles - ACP-196 - ARGX-110 - Betalutin - carfilzomib - CB-839 - copanlisib - DI-B4 - everolimus - FV-162 - FV-214 - GS-9973 - ibrutinib - idelalisib - IMO-8400 - INCB-39110 - INCB-40093 - IST-1097 - ixazomib citrate - lenalidomide - ofatumumab - oprozomib - pevonedistat hydrochloride - sapanisertib - selinexor - Small Molecules to Inhibit IRAK4 for Immunology and Oncology - spebrutinib besylate - venetoclax For more information visit http://www.researchandmarkets.com/research/8p...aldenstrom
PCYC: 261.25 (+1.70), INCY: 131.01 (+6.51), IDRA: 3.34 (+0.26), GILD: 109.63 (+2.38), CALA: 6.65 (+0.15), ABBV: 59.35 (-0.23), NVS: 96.55 (+0.28), CELGZ: 1.93 (+0.07), KPTI: 14.95 (+0.41)
J&J Initiates Filing for Multiple Myeloma Drug - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jun 08, 5:24PM CDT
Janssen Research & Development, LLC, a Johnson & Johnson (JNJ) company announced that the company has initiated the rolling submission of its BLA for pipeline candidate daratumumab to the FDA.
JNJ: 92.93 (+0.21), NVS: 96.55 (+0.28)
Genmab Announces Start of Rolling Submission of Biologics License Application for Daratumumab for Double Refractory Multiple Myeloma to the FDA
GlobeNewswire - Fri Jun 05, 10:54AM CDT
-- Janssen Biotech, Inc. initiates rolling submission of BLA to U.S. FDA for daratumumab in double refractory multiple myeloma
GEN: 7.03 (-0.10)
Halozyme-AbbVie Ink Deal for ENHANZE Platform, Shares Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jun 04, 8:50AM CDT
Halozyme Therapeutics, Inc. (HALO) entered into a global collaboration and license agreement with AbbVie.
HALO: 18.08 (+0.35), ABBV: 59.35 (-0.23)
Genmab Announces European Regulatory Submission for Daratumumab in Double Refractory Multiple Myeloma
GlobeNewswire - Wed Sep 09, 6:38AM CDT
-- MAA submitted to EMA by Janssen for daratumumab in multiple myeloma
GEN: 7.03 (-0.10)
Global Malignant Glioma Pipeline Review 2015
M2 - Tue Sep 08, 5:31AM CDT
Research and Markets (http://www.researchandmarkets.com/research/5ms2wz/malignant_glioma) has announced the addition of the "Malignant Glioma - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Malignant Glioma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Malignant Glioma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Advantagene, Inc. - Amgen Inc. - AstraZeneca Plc - BBB Therapeutics B.V. - Eisai Co., Ltd. - Eli Lilly and Company - Genmab A/S - Lipopharma Therapeutics SL - MediGene AG - Nuo Therapeutics, Inc. - Pfizer Inc. - Stemline Therapeutics, Inc. - Tiziana Life Sciences Plc - Vicus Therapeutics, LLC - ZIOPHARM Oncology, Inc. For more information visit http://www.researchandmarkets.com/research/5m...ant_glioma
ZIOP: 10.62 (+0.80), PFE: 32.97 (+0.35), AZN: 33.30 (+0.02), AMGN: 153.21 (+0.07), LLY: 81.80 (+0.96), STML: 10.84 (+0.59)
U.S. FDA Grants Priority Review for Daratumumab for Double Refractory Multiple Myeloma
GlobeNewswire - Fri Sep 04, 1:25PM CDT
-- U.S. FDA grants Priority Review to daratumumab
GEN: 7.03 (-0.10)
Major Shareholder Announcement
GlobeNewswire - Wed Sep 02, 3:14PM CDT
Company Announcement
GEN: 7.03 (-0.10)
Genmab Enters Commercial License Agreement with Novo Nordisk for DuoBody Technology
GlobeNewswire - Fri Aug 14, 5:37AM CDT
-- Two commercial DuoBody
NVO: 56.95 (+0.37), GEN: 7.03 (-0.10)
Genmab Announces Financial Results for the First Half of 2015
GlobeNewswire - Wed Aug 12, 12:59AM CDT
Interim Report First Half 2015
Bladder Cancer Pipeline Review, H1 2015 - 80 Companies & 119 Drug Profiles
M2 - Fri Jul 31, 8:42AM CDT
Research and Markets (http://www.researchandmarkets.com/research/shdv3w/bladder_cancer) has announced the addition of the "Bladder Cancer - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Bladder Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Bladder Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development (Partial List) - Advaxis, Inc. - Alligator Bioscience AB - Alnylam Pharmaceuticals, Inc. - Altor BioScience Corporation - Amgen Inc. - AndroScience Corporation - APIM Therapeutics AS - Arno Therapeutics, Inc. - Ascenta Therapeutics, Inc. - Astellas Pharma Inc. - AstraZeneca Plc - AuraSense Therapeutics, LLC - AVEO Pharmaceuticals, Inc. - AvidBiotics Corp. - Bavarian Nordic A/S - Bayer AG - BioCancell Ltd - Bioncotech Therapeutics S.L. - Biotest AG - cCAM Biotherapeutics Ltd. - Celgene Corporation - Cold Genesys, Inc. - Daiichi Sankyo Company, Limited - Dompe Farmaceutici S.p.A. - DormaTarg, Inc. - Eisai Co., Ltd. - Eli Lilly and Company - EntreChem, S.L. - Esperance Pharmaceuticals, Inc. - Evotec AG - F. Hoffmann-La Roche Ltd. - Gene Signal International SA - Genmab A/S - GlaxoSmithKline Plc - Heat Biologics, Inc. For more information visit http://www.researchandmarkets.com/research/sh...der_cancer
HTBX: 4.52 (+0.11), ADXS: 16.51 (+0.55), AMGN: 153.21 (+0.07), LLY: 81.80 (+0.96), GSK: 40.26 (+0.02), AZN: 33.30 (+0.02), AVEO: 1.36 (unch), CELGZ: 1.93 (+0.07)
Pemphigus Vulgaris Pipeline Review, H1 2015 - 5 Companies & 7 Drug Profiles
M2 - Tue Jul 28, 8:14AM CDT
Research and Markets (http://www.researchandmarkets.com/research/ms9fp4/pemphigus) has announced the addition of the "Pemphigus Vulgaris - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Pemphigus Vulgaris, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Pemphigus Vulgaris and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Biogen, Inc. - Genmab A/S - HanAll Biopharma Co., Ltd. - Immunomedics, Inc. - Novartis AG Drug Profiles - DP-C006 - HL-161 - ofatumumab - rituximab - T-Cell Therapy for Pemphigus Vulgaris - VAY-736 - veltuzumab For more information visit http://www.researchandmarkets.com/research/ms9fp4/pemphigus
IMMU: 2.22 (+0.01), NVS: 96.55 (+0.28)
Genmab Announces Submission of Supplemental Biologics License Application to FDA for Ofatumumab as Maintenance Therapy for Relapsed CLL
GlobeNewswire - Wed Jul 22, 7:27AM CDT
Company Announcement
GEN: 7.03 (-0.10)
Endometrial Cancer Therapeutics Pipeline Review, H1 2015 - 35 Companies & 48 Drug Profiles
M2 - Tue Jul 21, 3:45AM CDT
Research and Markets (http://www.researchandmarkets.com/research/psfwd9/endometrial) has announced the addition of the "Endometrial Cancer - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Endometrial Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Endometrial Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Acceleron Pharma, Inc. - Aeterna Zentaris Inc. - Ariad Pharmaceuticals, Inc. - Arno Therapeutics, Inc. - ArQule, Inc. - AstraZeneca Plc - AVEO Pharmaceuticals, Inc. - BioMarin Pharmaceutical Inc. - Boehringer Ingelheim GmbH - Critical Outcome Technologies Inc. - Daiichi Sankyo Company, Limited - Eisai Co., Ltd. - Esperance Pharmaceuticals, Inc. - Exelixis, Inc. - Farmsintez - Galena Biopharma, Inc. - Genentech, Inc. - Genmab A/S - GlaxoSmithKline Plc - Gradalis Inc. - ImmunoGen, Inc. - Incyte Corporation - Karyopharm Therapeutics, Inc. - Merck & Co., Inc. - Merck KGaA - Millennium Pharmaceuticals, Inc. - Novartis AG - OncoHoldings, Inc. - Oncothyreon Inc. - Otsuka Holdings Co., Ltd. - Pharma Mar, S.A. - Puma Biotechnology, Inc. - Sanofi - Scancell Holdings Plc - Shenogen Pharma Group Ltd. Drug Profiles - (ponatinib hydrochloride ridaforolimus) - ???Pb-TCMC-Trastuzumab - AEZS-125 - afuresertib hydrochloride trametinib dimethyl sulfoxide - ARQ-092 - AV-203 - AZD-2014 - AZD-5363 - buparlisib hydrochloride - cabozantinib s-malate - cancer vaccine - Cell Therapy for Oncology - CLR-457 - COTI-2 - cridanimod - dalantercept - EP-200 - epacadostat - everolimus - FROST-450 - GALE-301 - GDC-0927 - GSK-2636771 - HO-3867 - HuMax-TF-ADC - INCB-54828 - lenvatinib - lurbinectedin - mirvetuximab soravtansine - MK-2206 - Modi-1 - Monoclonal Antibody to Inhibit L1CAM for Ovarian and Endometrial Cancer - neratinib - nintedanib - onapristone ER For more information visit http://www.researchandmarkets.com/research/ps...ndometrial
BMRN: 132.88 (-0.20), ARQL: 1.71 (-0.01), GALE: 1.70 (-0.01), EXEL: 5.91 (+0.04), XLRN: 33.62 (+1.44), INCY: 131.01 (+6.51), IMGN: 13.86 (+0.59), GSK: 40.26 (+0.02), ONTY: 3.30 (-0.09), AZN: 33.30 (+0.02), MRK: 52.09 (-0.63), AVEO: 1.36 (unch), PBYI: 103.28 (+6.59), KPTI: 14.95 (+0.41), NVS: 96.55 (+0.28)
Major Shareholder Announcement for Genmab A/S
GlobeNewswire - Fri Jul 10, 10:54AM CDT
Genmab A/S (OMX:GEN) announces under reference to Section 29 of the Danish Securities Trading Act that ATP has informed us that ATP and AES as of July 10, 2015 have reduced their ownership of the share capital and voting rights in Genmab A/S to below the 5% threshold.
GEN: 7.03 (-0.10)
Genmab Announces Completion of Rolling Submission of Biologics License Application for Daratumumab in Multiple Myeloma and Achievement of a USD 15 Million Milestone
GlobeNewswire - Thu Jul 09, 12:53PM CDT
-- Submission of rolling BLA to US FDA for daratumumab in multiple myeloma completed by Janssen Biotech, Inc.
GEN: 7.03 (-0.10)
Relapsing Remitting Multiple Sclerosis (RRMS) Therapeutics Pipeline Review, H1 2015 - 27 Companies & 33 Drug profiles
M2 - Thu Jul 09, 9:49AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hdmmpc/relapsing) has announced the addition of the "Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Relapsing Remitting Multiple Sclerosis (RRMS), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Relapsing Remitting Multiple Sclerosis (RRMS) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AbbVie Inc. - Actelion Ltd - Allozyne, Inc. - Amarna Therapeutics B.V. - Antisense Therapeutics Limited - Biogen, Inc. - Cognosci, Inc. - F. Hoffmann-La Roche Ltd. - Forward Pharma A/S - Genmab A/S - GlaxoSmithKline plc - Iltoo Pharma - Mapi Pharma Ltd. - MedImmune, LLC - Merck KGaA - Mitsubishi Tanabe Pharma Corporation - Neurotec Pharma SL - Novartis AG - Nuron Biotech, Inc. - Octapharma AG - Opexa Therapeutics, Inc. - RedHill Biopharma Ltd. - Sanofi - Synthetic Biologics, Inc. - Teva Pharmaceutical Industries Limited - XenoPort, Inc. - Zydus Cadila Healthcare Limited Drug Profiles - (rifabutin clarithromycin clofazimine) - aldesleukin - ATL-1102 - ATXMS-1467 - AZ-17 - Cell Therapy for Relapsing Remitting Multiple Sclerosis - COG-133 - daclizumab - diazoxide - dimethyl fumarate - estriol - Gene Therapy for Relapsing and Remitting Multiple Sclerosis - glatiramer acetate ER - GSK-239512 - Guanabenz - HR-411 - hydralazine - imilecleucel-t - immune globulin (human) - interferon beta-1b - laquinimod sodium - MEDI-551 - MT-1303 - ofatumumab - olesoxime - opicinumab - Pegylated Interferon-Beta-1b - ponesimod - siponimod - Small Molecule to Target CTLA4 and IFNGR for RRMS - vatelizumab - VAY-736 - XP-23829 For more information visit http://www.researchandmarkets.com/research/hdmmpc/relapsing
MAPI: (), RDHL: 14.47 (+0.62), GSK: 40.26 (+0.02), XNPT: 7.14 (+0.25), SYN: 2.62 (+0.18), OPXA: 0.44 (unch), FWP: 25.68 (+0.46), TEVA: 63.66 (+1.62), ABBV: 59.35 (-0.23), NVS: 96.55 (+0.28)
Lung Adenocarcinoma Pipeline Review, H1 2015 - 19 Companies & 27 Drug Profiles
M2 - Thu Jul 09, 6:34AM CDT
Research and Markets (http://www.researchandmarkets.com/research/3vrdth/lung) has announced the addition of the "Lung Adenocarcinoma - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Lung Adenocarcinoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Lung Adenocarcinoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Amgen Inc. - Astex Pharmaceuticals, Inc. - AstraZeneca PLC - AVEO Pharmaceuticals, Inc. - Axelar AB - Bayer AG - BioNumerik Pharmaceuticals, Inc. - Boehringer Ingelheim GmbH - DiNonA Inc. - Eisai Co., Ltd. - Genentech, Inc. - Genmab A/S - Immunomedics, Inc. - Incyte Corporation - Medisyn Technologies, Inc. - Pfizer Inc. - Sanofi - VG Life Sciences, Inc. - Vichem Chemie Research Ltd. Drug Profiles - 4-B4 - afatinib - AV-203 - AXL-1717 - AZD-6738 - BAY-1163877 - Cell Therapy to Activate CD40L and GM-CSF for Metastatic Lung Adenocarcinoma - dacomitinib - DBPR-112 - dimesna - hydroxychloroquine sorafenib tosylate - Interferon Lambda-1 Linked Fab Dimer - lenvatinib - MAG-Tn3 - MT-477 - ruxolitinib phosphate - SAR-408701 - Small Molecule for Cancer - Small Molecule to Inhibit EGFR for Oncology - Small Molecules to Activate PKM2 for Lung Adenocarcinoma - Small Molecules to Inhibit Lactate Dehydrogenase for Lung Adenocarcinoma - SNX-5422 - solitomab - Stem Cell Therapy for Oncology - TdCyd - TF-011 Monomethyl Auristatin E - Vaccine for Lung Adenocarcinoma For more information visit http://www.researchandmarkets.com/research/3vrdth/lung
IMMU: 2.22 (+0.01), PFE: 32.97 (+0.35), INCY: 131.01 (+6.51), AZN: 33.30 (+0.02), AVEO: 1.36 (unch), AMGN: 153.21 (+0.07)
Genmab Announces European Regulatory Submission for Ofatumumab as Maintenance Therapy for Relapsed CLL
GlobeNewswire - Tue Jul 07, 6:40AM CDT
Company Announcement
GEN: 7.03 (-0.10)
B-Cell Non-Hodgkin Lymphoma - Pipeline Review, H1 2015 - Profiles of 90 Companies
M2 - Thu Jun 11, 6:13AM CDT
Research and Markets (http://www.researchandmarkets.com/research/4w5fzl/bcell) has announced the addition of the "B-Cell Non-Hodgkin Lymphoma - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for B-Cell Non-Hodgkin Lymphoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for B-Cell Non-Hodgkin Lymphoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - B-Cell Non-Hodgkin Lymphoma Overview - Therapeutics Development - B-Cell Non-Hodgkin Lymphoma - Therapeutics under Development by Companies - B-Cell Non-Hodgkin Lymphoma - Therapeutics under Investigation by Universities/Institutes - B-Cell Non-Hodgkin Lymphoma - Pipeline Products Glance - B-Cell Non-Hodgkin Lymphoma - Products under Development by Companies - B-Cell Non-Hodgkin Lymphoma - Products under Investigation by Universities/Institutes - B-Cell Non-Hodgkin Lymphoma - Companies Involved in Therapeutics Development - B-Cell Non-Hodgkin Lymphoma - Therapeutics Assessment - Drug Profiles - B-Cell Non-Hodgkin Lymphoma - Recent Pipeline Updates - B-Cell Non-Hodgkin Lymphoma - Dormant Projects - B-Cell Non-Hodgkin Lymphoma - Discontinued Products - B-Cell Non-Hodgkin Lymphoma - Product Development Milestones - Appendix Companies Mentioned - Affimed Therapeutics AG - Bristol-Myers Squibb Company - Emergent BioSolutions Inc. - EpiZyme, Inc. - Erytech Pharma SA - F. Hoffmann-La Roche Ltd. - Genentech, Inc. - Genmab A/S - Gilead Sciences, Inc. - GlaxoSmithKline plc - Idera Pharmaceuticals, Inc. - Immune System Therapeutics Ltd. - ImmunoGen, Inc. - Merck & Co., Inc. - Millennium Pharmaceuticals, Inc. - Mirati Therapeutics Inc. - Molecular Templates Inc. - MorphoSys AG - Nordic Nanovector AS - Portola Pharmaceuticals, Inc. - Priaxon AG - ProNAi Therapeutics, Inc. - Redx Pharma Ltd - Regeneron Pharmaceuticals, Inc. - Respiratorius AB - Rhizen Pharmaceuticals SA - Sandoz Inc. - Sanofi - Takeda Pharmaceutical Company Limited - Teva Pharmaceutical Industries Limited - TG Therapeutics, Inc. For more information visit http://www.researchandmarkets.com/research/4w5fzl/bcell
PTLA: 49.77 (+3.03), EBS: 32.58 (+0.39), IMGN: 13.86 (+0.59), TGTX: 11.83 (+0.37), EPZM: 20.70 (+0.23), BMY: 59.22 (+0.47), GSK: 40.26 (+0.02), IDRA: 3.34 (+0.26), GILD: 109.63 (+2.38), MRK: 52.09 (-0.63), TEVA: 63.66 (+1.62), MRTX: 43.38 (+8.58), REGN: 533.30 (+2.08)
Waldenstrom Macroglobulinemia - Pipeline Review, H1 2015 - 18 Companies & 27 Drug Profiles
M2 - Wed Jun 10, 4:20AM CDT
Research and Markets (http://www.researchandmarkets.com/research/8pl7hb/waldenstrom) has announced the addition of the "Waldenstrom Macroglobulinemia - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Waldenstrom Macroglobulinemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Waldenstrom Macroglobulinemia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AbbVie Inc. - arGEN-X BV - Bayer AG - Calithera Biosciences, Inc. - Celgene Corporation - Genmab A/S - Gilead Sciences, Inc. - Idera Pharmaceuticals, Inc. - Immune System Therapeutics Ltd. - Incyte Corporation - Karyopharm Therapeutics, Inc. - Merck KGaA - Millennium Pharmaceuticals, Inc. - Nimbus Therapeutics, LLC - Nordic Nanovector AS - Novartis AG - Onyx Pharmaceuticals, Inc. - Pharmacyclics, Inc. Drug Profiles - ACP-196 - ARGX-110 - Betalutin - carfilzomib - CB-839 - copanlisib - DI-B4 - everolimus - FV-162 - FV-214 - GS-9973 - ibrutinib - idelalisib - IMO-8400 - INCB-39110 - INCB-40093 - IST-1097 - ixazomib citrate - lenalidomide - ofatumumab - oprozomib - pevonedistat hydrochloride - sapanisertib - selinexor - Small Molecules to Inhibit IRAK4 for Immunology and Oncology - spebrutinib besylate - venetoclax For more information visit http://www.researchandmarkets.com/research/8p...aldenstrom
PCYC: 261.25 (+1.70), INCY: 131.01 (+6.51), IDRA: 3.34 (+0.26), GILD: 109.63 (+2.38), CALA: 6.65 (+0.15), ABBV: 59.35 (-0.23), NVS: 96.55 (+0.28), CELGZ: 1.93 (+0.07), KPTI: 14.95 (+0.41)
J&J Initiates Filing for Multiple Myeloma Drug - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jun 08, 5:24PM CDT
Janssen Research & Development, LLC, a Johnson & Johnson (JNJ) company announced that the company has initiated the rolling submission of its BLA for pipeline candidate daratumumab to the FDA.
JNJ: 92.93 (+0.21), NVS: 96.55 (+0.28)
Genmab Announces Start of Rolling Submission of Biologics License Application for Daratumumab for Double Refractory Multiple Myeloma to the FDA
GlobeNewswire - Fri Jun 05, 10:54AM CDT
-- Janssen Biotech, Inc. initiates rolling submission of BLA to U.S. FDA for daratumumab in double refractory multiple myeloma
GEN: 7.03 (-0.10)
Halozyme-AbbVie Ink Deal for ENHANZE Platform, Shares Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jun 04, 8:50AM CDT
Halozyme Therapeutics, Inc. (HALO) entered into a global collaboration and license agreement with AbbVie.
HALO: 18.08 (+0.35), ABBV: 59.35 (-0.23)
